Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings

JAMA Intern Med. 2023 Jan 1;183(1):82-84. doi: 10.1001/jamainternmed.2022.5419.

Authors

Alexander C Egilman¹, Victor L Van de Wiele¹, Benjamin N Rome¹, Jonathan J Darrow¹, S Sean Tu^{1

2}, Aaron S Kesselheim¹, Ameet Sarpatwari¹

Affiliations

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² West Virginia University College of Law, Morgantown.

No abstract available

Plain language summary

This cohort study assesses the frequency of approval and marketing of skinny-label biosimilars and their savings to Medicare.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Biosimilar Pharmaceuticals*
Drug Approval
Humans
Marketing
Medicare
United States

Substances

Biosimilar Pharmaceuticals